Inactive Instrument

Opiant Pharmaceuticals, Inc.

Equities

OPNT

US6837501039

Biotechnology & Medical Research

Opiant Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2021

May 11, 2021 at 04:05 pm

Opiant Pharmaceuticals, Inc. provided earnings guidance for the full year 2021. Based on the mid-range of the full-year 2021 guidance for sales of NARCAN Nasal Spray provided by EBS, of $315 million, the company continues to expect full-year 2021 royalty revenue from the sale of NARCAN Nasal Spray of approximately $27.8 million.

Latest news about Opiant Pharmaceuticals, Inc.

Indivior completes acquisition of Opiant Pharmaceuticals	23-03-02	AN
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	23-03-02	MT
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from NASDAQ Composite Index	23-03-02	CI
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from S&P TMI Index	23-03-02	CI
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders.	23-03-01	CI
Transcript : Opiant Pharmaceuticals, Inc. - Shareholder/Analyst Call	23-03-01
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals	23-02-07	MT
Indivior announces expiry of waiting period for Opiant purchase	23-02-06	AN
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires	23-02-06	MT
Indivior Nears Acquisition of Opiant Pharmaceuticals	23-02-06	MT
Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals	23-01-26	RE
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy	23-01-20	MT
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	23-01-19	CI
Insider Sell: Opiant Pharmaceuticals	23-01-05	MT
Opiant Pharmaceuticals Completes Rolling Submission of New Drug Application for Potential Opioid Overdose Drug	22-11-23	MT
Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose	22-11-22	CI
Healthcare Shares Climb, Beating Broader Market -- Healthcare Roundup	22-11-14	DJ
Top Midday Gainers	22-11-14	MT
MarketScreener's World Press Review : November 14, 2022	22-11-14
Wall Street Set to Open Lower After Red Hot Week; Fed Gov Warns Inflation Fight Not Over	22-11-14	MT
US Futures Nudge Lower Premarket as Fed Governor Warns Inflation Fight Not Over	22-11-14	MT
Top Premarket Gainers	22-11-14	MT
Transcript : Indivior PLC, Opiant Pharmaceuticals, Inc. - M&A Call	22-11-14
Indivior buys Opiant creating "comprehensive" treatment platform	22-11-14	AN
Opiant Pharmaceuticals to Be Acquired by Indivior	22-11-14	MT

Chart Opiant Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.69%	21.83B
GENMAB A/S	-10.23%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs